Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ACQUIRED EXCLUSIVE GLOBAL RIGHTS TO LYL273, A NOVEL GCC-TARGETED CAR T-CELL PRODUCT CANDIDATE THAT HAS DEMONSTRATED A 67% OVERALL RESPONSE RATE, AN 83% DISEASE CONTROL RATE AND A MANAGEABLE SAFETY PROFILE AT THE HIGHEST DOSE LEVEL STUDIED TO DATE IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER IN AN ONGOING U.S. PHASE 1 CLINICAL TRIAL RECEIVED RMAT DESIGNATION FROM THE U.S. FDA FOR RONDE-CEL FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY LBCL RECEIVING TREATMENT IN THE SECOND-LINE (2L) SETTING ANNOUNCED THAT TWO ABSTRACTS HIGHLIGHTING NEW CLINICAL AND TRANSLATIONAL DATA FROM THE PHASE 1/2 CLINICAL TRIAL OF RONDECEL FOR THE TREATMENT OF AGGRESSIVE LARGE B-CELL LYMPHOMA HAVE BEEN ACCEPTED FOR ORAL PRESENTATION AT THE ASH 67TH ANNUAL MEETING AND EXPOSITION IN DECEMBER ANNOUNCED THE INITIATION OF PINACLE - H2H, A PHASE 3 HEAD-TO-HEAD CAR T-CELL THERAPY CLINICAL TRIAL IN AGGRESSIVE LARGE B-CELL LYMPHOMA IN THE 2L SETTING FORMED A PINACLE  H2H STEERING COMMITTEE COMPRISED OF A DISTINGUISHED GROUP OF LYMPHOMA AND CELL THERAPY EXPERTS CASH OF APPROXIMATELY $320MILLION AT THE END OF THE THIRD QUARTER OF 2025; CURRENT CASH IS EXPECTED TO SUPPORT ADVANCING PIPELINE INTO 2027 THROUGH KEY CLINICAL MILESTONES SOUTH SAN FRANCISCO, CALIF., NOV. 12, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

LYELL IMMUNOPHARMA REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE THIRD QUARTER 2025

LYL273 HAS DEMONSTRATED A 67% OVERALL RESPONSE RATE, AN 83% DISEASE CONTROL RATE, AND A MANAGEABLE SAFETY PROFILE AT THE HIGHEST DOSE LEVEL STUDIED TO DATE IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER ENROLLED IN AN ONGOING U.S. PHASE 1 CLINICAL TRIAL LYL273 IS A GCC-TARGETED CAR T-CELL PRODUCT CANDIDATE ARMED WITH ENHANCEMENTS DESIGNED TO IMPROVE CAR T-CELL EXPANSION AND CANCER CELL KILLING LYELL MANAGEMENT WILL HOST AN INVESTOR WEBCAST AT 8:30 AM ET TODAY SOUTH SAN FRANCISCO, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED IT HAS STRENGTHENED ITS SOLID TUMOR PIPELINE BY ACQUIRING GLOBAL RIGHTS TO LYL273 (FORMERLY GCC19CART), A NOVEL AUTOLOGOUS GUANYLYL CYCLASE-C (GCC)-TARGETED CAR T-CELL PRODUCT CANDIDATE FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) AND OTHER GCC-EXPRESSING CANCERS, FROM INNOVATIVE CELLULAR THERAPEUTICS (ICT).

LYELL IMMUNOPHARMA ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO A NEXT-GENERATION CAR T-CELL PRODUCT CANDIDATE IN CLINICAL DEVELOPMENT FOR METASTATIC COLORECTAL CANCER

SOUTH SAN FRANCISCO, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT TWO ABSTRACTS HIGHLIGHTING NEW CLINICAL AND TRANSLATIONAL DATA FROM THE PHASE 1/2 CLINICAL TRIAL OF RONDECABTAGENE AUTOLEUCEL (RONDE-CEL, ALSO KNOWN AS LYL314) FOR THE TREATMENT OF AGGRESSIVE LARGE B-CELL LYMPHOMA (LBCL) WILL BE PRESENTED AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION.

LYELL ANNOUNCES TWO ORAL PRESENTATIONS FROM THE PHASE 1/2 CLINICAL TRIAL OF RONDE-CEL FOR THE TREATMENT OF AGGRESSIVE LARGE B-CELL LYMPHOMA AT THE 67TH ASH ANNUAL MEETING AND EXPOSITION

Lyell Immunopharma, Inc.

LYEL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Lyell Immunopharma, Inc.

LYEL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LYEL